Trial Outcomes & Findings for A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (NCT NCT05068284)
NCT ID: NCT05068284
Last Updated: 2024-10-03
Results Overview
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 (worst) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
176 participants
Primary outcome timeframe
Baseline to Week 12
Results posted on
2024-10-03
Participant Flow
In this Double-Blind study, subjects with Crohn's Disease (CD) were randomized into 5 groups for 12 weeks (Induction Period). At week 12, subjects were categorized as responders or non-responders. Responders were re-randomized into a 40-Week Maintenance Period. Non-responders were re-randomized into the 12-Week Re-Induction Period. At week 12 of the re-induction period, those achieving clinical/endoscopic response were re-randomized into the Maintenance Period.
Participant milestones
| Measure |
Placebo
Participants received Placebo Intravenous (IV) during Week (Wk) 0, followed by Placebo Subcutaneous (SC) Every Other Week (EOW) until week 12
Maintenance Period:
Participants received Placebo SC, EOW for 40 weeks
|
ABBV-154 150mg IV, 80mg SC EOW
Participants received a loading dose of 150mg IV of ABBV-154 during Wk 0, followed by ABBV-154 80mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 300mg IV, 230mg SC EOW
Participants received 300mg IV of ABBV-154 during Wk 0, followed by ABBV-154 230mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC EOW
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC E4W
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 4 and Wk 8; every 4 weeks (E4W)
|
ABBV-154 80mg SC EOW
During the Maintenance Period, participants received ABBV-154 80mg SC only. No IV was administered during the Maintenance Period.
|
ABBV-154 230mg SC EOW
During the Maintenance Period, participants received ABBV-154 230mg SC only. No IV was administered during the Maintenance Period.
|
MP: Placebo Responders; ABBV-154 80mg SC
During the Maintenance Period, placebo responders received ABBV-154 80mg SC only. No IV was administered during the Maintenance Period.
|
|---|---|---|---|---|---|---|---|---|
|
Double-Blind Induction (12 Weeks)
STARTED
|
21
|
20
|
22
|
20
|
23
|
0
|
0
|
0
|
|
Double-Blind Induction (12 Weeks)
COMPLETED
|
12
|
15
|
12
|
15
|
12
|
0
|
0
|
0
|
|
Double-Blind Induction (12 Weeks)
NOT COMPLETED
|
9
|
5
|
10
|
5
|
11
|
0
|
0
|
0
|
|
Double-Blind Re-Induction (12 Weeks)
STARTED
|
0
|
0
|
12
|
12
|
0
|
0
|
0
|
0
|
|
Double-Blind Re-Induction (12 Weeks)
COMPLETED
|
0
|
0
|
9
|
6
|
0
|
0
|
0
|
0
|
|
Double-Blind Re-Induction (12 Weeks)
NOT COMPLETED
|
0
|
0
|
3
|
6
|
0
|
0
|
0
|
0
|
|
Double-Blind Maintenance (40 Weeks)
STARTED
|
18
|
0
|
0
|
0
|
0
|
14
|
13
|
4
|
|
Double-Blind Maintenance (40 Weeks)
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Double-Blind Maintenance (40 Weeks)
NOT COMPLETED
|
18
|
0
|
0
|
0
|
0
|
13
|
13
|
4
|
Reasons for withdrawal
| Measure |
Placebo
Participants received Placebo Intravenous (IV) during Week (Wk) 0, followed by Placebo Subcutaneous (SC) Every Other Week (EOW) until week 12
Maintenance Period:
Participants received Placebo SC, EOW for 40 weeks
|
ABBV-154 150mg IV, 80mg SC EOW
Participants received a loading dose of 150mg IV of ABBV-154 during Wk 0, followed by ABBV-154 80mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 300mg IV, 230mg SC EOW
Participants received 300mg IV of ABBV-154 during Wk 0, followed by ABBV-154 230mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC EOW
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC E4W
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 4 and Wk 8; every 4 weeks (E4W)
|
ABBV-154 80mg SC EOW
During the Maintenance Period, participants received ABBV-154 80mg SC only. No IV was administered during the Maintenance Period.
|
ABBV-154 230mg SC EOW
During the Maintenance Period, participants received ABBV-154 230mg SC only. No IV was administered during the Maintenance Period.
|
MP: Placebo Responders; ABBV-154 80mg SC
During the Maintenance Period, placebo responders received ABBV-154 80mg SC only. No IV was administered during the Maintenance Period.
|
|---|---|---|---|---|---|---|---|---|
|
Double-Blind Induction (12 Weeks)
Withdrawal by Subject
|
2
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Double-Blind Induction (12 Weeks)
Adverse Event
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
|
Double-Blind Induction (12 Weeks)
Study terminated by sponsor
|
7
|
2
|
6
|
5
|
10
|
0
|
0
|
0
|
|
Double-Blind Induction (12 Weeks)
Lack of Efficacy
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
|
Double-Blind Re-Induction (12 Weeks)
Adverse Event
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Double-Blind Re-Induction (12 Weeks)
Study terminated by sponsor
|
0
|
0
|
1
|
4
|
0
|
0
|
0
|
0
|
|
Double-Blind Re-Induction (12 Weeks)
Lack of Efficacy
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
|
Double-Blind Maintenance (40 Weeks)
Lack of efficacy w/o receiving ABBV-154 rescue
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Double-Blind Maintenance (40 Weeks)
Study terminated by sponsor after ABBV-154
|
8
|
0
|
0
|
0
|
0
|
3
|
1
|
0
|
|
Double-Blind Maintenance (40 Weeks)
AE w/o receiving ABBV-154 rescue
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Double-Blind Maintenance (40 Weeks)
WD by subject w/o receiving ABBV-154 rescue
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Double-Blind Maintenance (40 Weeks)
Lack of efficacy after receiving ABBV-154 rescue
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Double-Blind Maintenance (40 Weeks)
Study terminated by sponsor w/o receiving ABBV-154 rescue
|
6
|
0
|
0
|
0
|
0
|
10
|
11
|
3
|
|
Double-Blind Maintenance (40 Weeks)
Other
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
Baseline characteristics by cohort
| Measure |
Double-Blind Induction Phase: Placebo
n=21 Participants
Fixed dose placebo as described in the protocol.
Placebo: Intravenous (IV) infusion; Subcutaneous Injection.
|
Double-Blind Induction Phase: ABBV-154 150mg IV/ 80mg SC EOW
n=20 Participants
ABBV-154:
150 mg Intravenous (IV) Infusion and Subcutaneous Injection 80 mg (SC) at end of week (EOW) 12-week double-blind Induction Phase.
|
Double-Blind Induction Phase: ABBV-154 300mg IV/ 230mg SC EOW
n=22 Participants
ABBV-154:
300 mg Intravenous (IV) Infusion and Subcutaneous Injection 230 mg (SC) at end of week (EOW) 12-week double-blind Induction Phase.
|
Double-Blind Induction Phase: ABBV-154 600mg IV/ 530mg SC EOW
n=20 Participants
ABBV-154:
600 mg Intravenous (IV) Infusion and Subcutaneous Injection 530 mg (SC) at end of week (EOW) 12-week double-blind Induction Phase.
|
Double-Blind Induction Phase: ABBV-154 600mg IV/ 530mg SC E4W
n=23 Participants
ABBV-154:
600 mg Intravenous (IV) Infusion and Subcutaneous Injection 530 mg (SC) every 4 weeks (E4W) 12-week double-blind Induction Phase.
|
Total
n=106 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
38.8 years
STANDARD_DEVIATION 13.23 • n=5 Participants
|
41.7 years
STANDARD_DEVIATION 14.27 • n=7 Participants
|
39.6 years
STANDARD_DEVIATION 12.23 • n=5 Participants
|
43.1 years
STANDARD_DEVIATION 14.37 • n=4 Participants
|
42.0 years
STANDARD_DEVIATION 14.20 • n=21 Participants
|
41.0 years
STANDARD_DEVIATION 13.50 • n=10 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
43 Participants
n=10 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
14 Participants
n=5 Participants
|
11 Participants
n=4 Participants
|
13 Participants
n=21 Participants
|
63 Participants
n=10 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
21 Participants
n=5 Participants
|
20 Participants
n=7 Participants
|
21 Participants
n=5 Participants
|
20 Participants
n=4 Participants
|
23 Participants
n=21 Participants
|
105 Participants
n=10 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Asian
|
4 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
22 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
|
Race (NIH/OMB)
White
|
17 Participants
n=5 Participants
|
15 Participants
n=7 Participants
|
17 Participants
n=5 Participants
|
14 Participants
n=4 Participants
|
17 Participants
n=21 Participants
|
80 Participants
n=10 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
|
Baseline Simple Endoscopic Score for Crohn's Disease (SES-CD) for ITT1 (all enrolled)
|
14.86 SES-CD score (0-56)
STANDARD_DEVIATION 8.928 • n=5 Participants
|
13.53 SES-CD score (0-56)
STANDARD_DEVIATION 6.816 • n=7 Participants
|
16.73 SES-CD score (0-56)
STANDARD_DEVIATION 10.533 • n=5 Participants
|
16.13 SES-CD score (0-56)
STANDARD_DEVIATION 6.472 • n=4 Participants
|
14.65 SES-CD score (0-56)
STANDARD_DEVIATION 6.748 • n=21 Participants
|
15.19 SES-CD score (0-56)
STANDARD_DEVIATION 8.011 • n=10 Participants
|
PRIMARY outcome
Timeframe: Baseline to Week 12Population: ITT1 Population for whom data was collected and available for analysis.
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 (worst) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Outcome measures
| Measure |
Placebo
n=11 Participants
Participants received Placebo Intravenous (IV) during Week (Wk) 0, followed by Placebo Subcutaneous (SC) Every Other Week (EOW) until week 12
|
ABBV-154 150mg IV, 80mg SC EOW
n=14 Participants
Participants received 150mg IV of ABBV-154 during Wk 0, followed by ABBV-154 80mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 300mg IV, 230mg SC EOW
n=12 Participants
Participants received 300mg IV of ABBV-154 during Wk 0, followed by ABBV-154 230mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC EOW
n=14 Participants
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC E4W
n=11 Participants
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 4 and Wk 8; every 4 weeks (E4W)
|
|---|---|---|---|---|---|
|
Percentage of Participants Achieving Endoscopic Response Per Simple Endoscopic Score for Crohn's Disease (SES-CD)
|
0 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: Induction Period Week 12Population: ITT1 Population for whom data was collected and available for analysis.
The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. Clinical remission is defined as CDAI \< 150.
Outcome measures
| Measure |
Placebo
n=12 Participants
Participants received Placebo Intravenous (IV) during Week (Wk) 0, followed by Placebo Subcutaneous (SC) Every Other Week (EOW) until week 12
|
ABBV-154 150mg IV, 80mg SC EOW
n=14 Participants
Participants received 150mg IV of ABBV-154 during Wk 0, followed by ABBV-154 80mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 300mg IV, 230mg SC EOW
n=13 Participants
Participants received 300mg IV of ABBV-154 during Wk 0, followed by ABBV-154 230mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC EOW
n=14 Participants
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC E4W
n=10 Participants
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 4 and Wk 8; every 4 weeks (E4W)
|
|---|---|---|---|---|---|
|
Percentage of Participants Achieving Clinical Remission Per Crohn's Disease Activity Index (CDAI)
|
2 Participants
|
4 Participants
|
6 Participants
|
5 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: Induction Period Week 12Population: ITT1 Population for whom data was collected and available for analysis.
Clinical remission is defined as average daily liquid or very soft stool SF \<= 2.8 and not worse than Baseline and average daily AP score \<= 1 and not worse than Baseline.
Outcome measures
| Measure |
Placebo
n=13 Participants
Participants received Placebo Intravenous (IV) during Week (Wk) 0, followed by Placebo Subcutaneous (SC) Every Other Week (EOW) until week 12
|
ABBV-154 150mg IV, 80mg SC EOW
n=15 Participants
Participants received 150mg IV of ABBV-154 during Wk 0, followed by ABBV-154 80mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 300mg IV, 230mg SC EOW
n=13 Participants
Participants received 300mg IV of ABBV-154 during Wk 0, followed by ABBV-154 230mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC EOW
n=15 Participants
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 2 and EOW until Week 12
|
ABBV-154 600mg IV, 530mg SC E4W
n=11 Participants
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 4 and Wk 8; every 4 weeks (E4W)
|
|---|---|---|---|---|---|
|
Percentage of Participants Achieving Clinical Remission Per Average Daily Liquid or Very Soft Stool Frequency (SF) and Average Daily Abdominal Pain (AP) Score (SF/AP)
|
2 Participants
|
4 Participants
|
7 Participants
|
6 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Week 40 in the Maintenance PeriodPopulation: Data were not collected for this outcome due to early termination of the study.
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Week 40 in the Maintenance PeriodPopulation: Data were not collected for this outcome due to early termination of the study.
The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. Clinical remission is defined as CDAI \< 150.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Week 40 in the Maintenance PeriodPopulation: Data were not collected for this outcome due to early termination of the study.
Clinical remission is defined as average daily liquid or very soft SF \<= 2.8 and not worse than Baseline and average daily AP score \<= 1 and not worse than Baseline.
Outcome measures
Outcome data not reported
Adverse Events
Induction Period: Placebo
Serious events: 3 serious events
Other events: 7 other events
Deaths: 0 deaths
Induction Period: ABBV-154 150mg IV, 80mg SC
Serious events: 3 serious events
Other events: 12 other events
Deaths: 0 deaths
Induction Period: ABBV-154 300mg IV, 230mg SC
Serious events: 2 serious events
Other events: 11 other events
Deaths: 0 deaths
Induction Period: ABBV-154 600mg IV, 530mg SC
Serious events: 0 serious events
Other events: 14 other events
Deaths: 0 deaths
Induction Period: ABBV-154 600mg IV, 530mg SC E4W
Serious events: 3 serious events
Other events: 13 other events
Deaths: 0 deaths
IP: Placebo; ReIP: ABBV-154 300mg IV, 230mg SC
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
IP: Placebo; ReIP: ABBV-154 600mg IV, 530mg SC
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
IP: ABBV-154; ReIP: ABBV-154 300mg IV, 230mg SC
Serious events: 1 serious events
Other events: 5 other events
Deaths: 0 deaths
IP: ABBV-154; ReIP: ABBV-154 600mg IV, 530mg SC
Serious events: 2 serious events
Other events: 4 other events
Deaths: 0 deaths
MP: ABBV-154 Responders; Placebo SC
Serious events: 3 serious events
Other events: 9 other events
Deaths: 0 deaths
MP: ABBV-154 Responders; ABBV-154 80mg SC
Serious events: 1 serious events
Other events: 10 other events
Deaths: 0 deaths
MP: ABBV-154 Responders; ABBV-154 230mg SC
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
MP: Placebo Responders; ABBV-154 80mg SC
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Rescue ABBV-154 600mg IV, 230mg SC EOW
Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Induction Period: Placebo
n=21 participants at risk
Participants received Placebo Intravenous (IV) during Week (Wk) 0, followed by Placebo Subcutaneous (SC) Every Other Week (EOW) until week 12
|
Induction Period: ABBV-154 150mg IV, 80mg SC
n=20 participants at risk
Participants received 150mg IV of ABBV-154 during Wk 0, followed by ABBV-154 80mg SC during Wk 2 and EOW until Week 12
|
Induction Period: ABBV-154 300mg IV, 230mg SC
n=22 participants at risk
Participants received 300mg IV of ABBV-154 during Wk 0, followed by ABBV-154 230mg SC during Wk 2 and EOW until Week 12
|
Induction Period: ABBV-154 600mg IV, 530mg SC
n=20 participants at risk
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 2 and EOW until Week 12
|
Induction Period: ABBV-154 600mg IV, 530mg SC E4W
n=23 participants at risk
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 4 and Wk 8; every 4 weeks (E4W)
|
IP: Placebo; ReIP: ABBV-154 300mg IV, 230mg SC
n=4 participants at risk
Following Induction Period (IP): Non-responding, Placebo-dosed Participants were re-induced (ReIP) with ABBV-154 300mg IV (Wk 12), followed by 230mg SC (Wk 14) and EOW until Wk 24
|
IP: Placebo; ReIP: ABBV-154 600mg IV, 530mg SC
n=4 participants at risk
Following IP: Non-responding, Placebo-dosed Participants were ReIP with ABBV-154 600mg IV (Wk 12), followed by 530mg SC (Wk 14) and EOW until Wk 24
|
IP: ABBV-154; ReIP: ABBV-154 300mg IV, 230mg SC
n=8 participants at risk
Following IP: Non-responding, ABBV-154-dosed Participants were ReIP with ABBV-154 300mg IV (Wk 12), followed by 230mg SC (Wk 14) and EOW until Wk 24
|
IP: ABBV-154; ReIP: ABBV-154 600mg IV, 530mg SC
n=8 participants at risk
Following IP: Non-responding, ABBV-154-dosed Participants were ReIP with ABBV-154 600mg IV (Wk 12), followed by 530mg SC (Wk 14) and EOW until Wk 24
|
MP: ABBV-154 Responders; Placebo SC
n=18 participants at risk
Following IP: Responding, ABBV-154-dosed Participants received Placebo SC EOW during the maintenance period (MP) of 40 weeks
|
MP: ABBV-154 Responders; ABBV-154 80mg SC
n=14 participants at risk
Following IP: Responding, ABBV-154-dosed Participants received ABBV-154 80mg SC EOW during the maintenance period (MP) of 40 weeks
|
MP: ABBV-154 Responders; ABBV-154 230mg SC
n=13 participants at risk
Following IP: Responding, ABBV-154-dosed Participants received ABBV-154 230mg SC EOW during the maintenance period (MP) of 40 weeks
|
MP: Placebo Responders; ABBV-154 80mg SC
n=4 participants at risk
Following IP: Responding, Placebo-dosed Participants received ABBV-154 80mg SC EOW during the maintenance period (MP) of 40 weeks
|
Rescue ABBV-154 600mg IV, 230mg SC EOW
n=14 participants at risk
During MP:
Inadequate-Responding, Placebo or ABBV-154-dosed Participants received ABBV-154 600mg IV followed by 230mg SC Rescue Therapy
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
ABDOMINAL DISTENSION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
CROHN'S DISEASE
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
SMALL INTESTINAL OBSTRUCTION
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INFLAMMATION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Immune system disorders
INFUSION RELATED HYPERSENSITIVITY REACTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Immune system disorders
SERUM SICKNESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
ABDOMINAL ABSCESS
|
4.8%
1/21 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
ANAL ABSCESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
APPENDICITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
COLONIC ABSCESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
FOCAL PERITONITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
INFECTIOUS PLEURAL EFFUSION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
PNEUMONIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
URINARY TRACT INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
HYPOKALAEMIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Reproductive system and breast disorders
FEMALE GENITAL TRACT FISTULA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
Other adverse events
| Measure |
Induction Period: Placebo
n=21 participants at risk
Participants received Placebo Intravenous (IV) during Week (Wk) 0, followed by Placebo Subcutaneous (SC) Every Other Week (EOW) until week 12
|
Induction Period: ABBV-154 150mg IV, 80mg SC
n=20 participants at risk
Participants received 150mg IV of ABBV-154 during Wk 0, followed by ABBV-154 80mg SC during Wk 2 and EOW until Week 12
|
Induction Period: ABBV-154 300mg IV, 230mg SC
n=22 participants at risk
Participants received 300mg IV of ABBV-154 during Wk 0, followed by ABBV-154 230mg SC during Wk 2 and EOW until Week 12
|
Induction Period: ABBV-154 600mg IV, 530mg SC
n=20 participants at risk
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 2 and EOW until Week 12
|
Induction Period: ABBV-154 600mg IV, 530mg SC E4W
n=23 participants at risk
Participants received 600mg IV of ABBV-154 during Wk 0, followed by ABBV-154 530mg SC during Wk 4 and Wk 8; every 4 weeks (E4W)
|
IP: Placebo; ReIP: ABBV-154 300mg IV, 230mg SC
n=4 participants at risk
Following Induction Period (IP): Non-responding, Placebo-dosed Participants were re-induced (ReIP) with ABBV-154 300mg IV (Wk 12), followed by 230mg SC (Wk 14) and EOW until Wk 24
|
IP: Placebo; ReIP: ABBV-154 600mg IV, 530mg SC
n=4 participants at risk
Following IP: Non-responding, Placebo-dosed Participants were ReIP with ABBV-154 600mg IV (Wk 12), followed by 530mg SC (Wk 14) and EOW until Wk 24
|
IP: ABBV-154; ReIP: ABBV-154 300mg IV, 230mg SC
n=8 participants at risk
Following IP: Non-responding, ABBV-154-dosed Participants were ReIP with ABBV-154 300mg IV (Wk 12), followed by 230mg SC (Wk 14) and EOW until Wk 24
|
IP: ABBV-154; ReIP: ABBV-154 600mg IV, 530mg SC
n=8 participants at risk
Following IP: Non-responding, ABBV-154-dosed Participants were ReIP with ABBV-154 600mg IV (Wk 12), followed by 530mg SC (Wk 14) and EOW until Wk 24
|
MP: ABBV-154 Responders; Placebo SC
n=18 participants at risk
Following IP: Responding, ABBV-154-dosed Participants received Placebo SC EOW during the maintenance period (MP) of 40 weeks
|
MP: ABBV-154 Responders; ABBV-154 80mg SC
n=14 participants at risk
Following IP: Responding, ABBV-154-dosed Participants received ABBV-154 80mg SC EOW during the maintenance period (MP) of 40 weeks
|
MP: ABBV-154 Responders; ABBV-154 230mg SC
n=13 participants at risk
Following IP: Responding, ABBV-154-dosed Participants received ABBV-154 230mg SC EOW during the maintenance period (MP) of 40 weeks
|
MP: Placebo Responders; ABBV-154 80mg SC
n=4 participants at risk
Following IP: Responding, Placebo-dosed Participants received ABBV-154 80mg SC EOW during the maintenance period (MP) of 40 weeks
|
Rescue ABBV-154 600mg IV, 230mg SC EOW
n=14 participants at risk
During MP:
Inadequate-Responding, Placebo or ABBV-154-dosed Participants received ABBV-154 600mg IV followed by 230mg SC Rescue Therapy
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Hepatobiliary disorders
LIVER DISORDER
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Blood and lymphatic system disorders
LEUKOCYTOSIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Blood and lymphatic system disorders
LYMPHADENOPATHY
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Blood and lymphatic system disorders
LYMPHOPENIA
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Endocrine disorders
CUSHING'S SYNDROME
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Eye disorders
VISION BLURRED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
ABDOMINAL DISTENSION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
APHTHOUS ULCER
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
CONSTIPATION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
CROHN'S DISEASE
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
20.0%
4/20 • Number of events 4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
9.1%
2/22 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
21.4%
3/14 • Number of events 4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
50.0%
2/4 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
14.3%
2/14 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
DENTAL CARIES
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
DIARRHOEA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
HAEMATOCHEZIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
HAEMORRHOIDS THROMBOSED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
NAUSEA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
PROCTALGIA
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
RECTAL HAEMORRHAGE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Gastrointestinal disorders
VOMITING
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
ASTHENIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
11.1%
2/18 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
CHEST PAIN
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
FATIGUE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
FEELING ABNORMAL
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INFLUENZA LIKE ILLNESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE BRUISING
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE DRYNESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
10.0%
2/20 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE ERYTHEMA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE EXFOLIATION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE INDENTATION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE PRURITUS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE RASH
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
10.0%
2/20 • Number of events 4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
INJECTION SITE SWELLING
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
OEDEMA PERIPHERAL
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
PAIN
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
General disorders
PYREXIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
9.1%
2/22 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Immune system disorders
HYPERSENSITIVITY
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Immune system disorders
INFUSION RELATED HYPERSENSITIVITY REACTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
2/8 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Immune system disorders
SEASONAL ALLERGY
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
ANAL ABSCESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
BRONCHITIS VIRAL
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
CELLULITIS
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
CONJUNCTIVITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
COVID-19
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
10.0%
2/20 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
14.3%
2/14 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
15.4%
2/13 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
CRYPTOSPORIDIOSIS INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
CYSTITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
ESCHERICHIA INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
GASTROENTERITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
GINGIVITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
INFLUENZA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
NASOPHARYNGITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
15.0%
3/20 • Number of events 4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
ORAL CANDIDIASIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
ORAL HERPES
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
PARONYCHIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
PHARYNGITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
PNEUMONIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
RASH PUSTULAR
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
RECTAL ABSCESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
RESPIRATORY TRACT INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
SALMONELLOSIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
SINUSITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
SUBCUTANEOUS ABSCESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
TINEA INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
URINARY TRACT INFECTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
10.0%
2/20 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Infections and infestations
VIRAEMIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Injury, poisoning and procedural complications
FALL
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Injury, poisoning and procedural complications
PROCEDURAL PAIN
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Injury, poisoning and procedural complications
TOOTH FRACTURE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
ALANINE AMINOTRANSFERASE INCREASED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
ASPARTATE AMINOTRANSFERASE INCREASED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE INCREASED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
CLOSTRIDIUM TEST POSITIVE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
FAECAL CALPROTECTIN INCREASED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
LIVER FUNCTION TEST ABNORMAL
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
WEIGHT DECREASED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Investigations
WEIGHT INCREASED
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
13.0%
3/23 • Number of events 3 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
DECREASED APPETITE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
DEHYDRATION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
HYPOALBUMINAEMIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
HYPOKALAEMIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
HYPOPHOSPHATAEMIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
INCREASED APPETITE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Metabolism and nutrition disorders
IRON DEFICIENCY
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
4.8%
1/21 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
9.5%
2/21 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
15.4%
2/13 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Musculoskeletal and connective tissue disorders
JOINT SWELLING
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL CHEST PAIN
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Musculoskeletal and connective tissue disorders
TENDON PAIN
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SKIN PAPILLOMA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Nervous system disorders
DIZZINESS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Nervous system disorders
HEADACHE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
10.0%
2/20 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
21.7%
5/23 • Number of events 5 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Nervous system disorders
MIGRAINE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Nervous system disorders
OPHTHALMIC MIGRAINE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Nervous system disorders
SYNCOPE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Psychiatric disorders
AGITATION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Psychiatric disorders
DEPRESSED MOOD
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Psychiatric disorders
INSOMNIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Renal and urinary disorders
RENAL COLIC
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.7%
1/13 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Renal and urinary disorders
URINARY RETENTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Reproductive system and breast disorders
CERVICAL DYSPLASIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Reproductive system and breast disorders
PROSTATOMEGALY
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Respiratory, thoracic and mediastinal disorders
COUGH
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 3 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPHONIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Respiratory, thoracic and mediastinal disorders
NASAL CONGESTION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
8.7%
2/23 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
ACNE
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
10.0%
2/20 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.3%
1/23 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
ALOPECIA
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
10.0%
2/20 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
DERMATITIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
DERMATITIS ACNEIFORM
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
DERMATITIS CONTACT
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
DERMATITIS PSORIASIFORM
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.6%
1/18 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
ECCHYMOSIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
ERYTHROSIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
HYPERHIDROSIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
LICHENOID KERATOSIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
NIGHT SWEATS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
7.1%
1/14 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
PRURITUS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
4.5%
1/22 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
11.1%
2/18 • Number of events 2 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
PSORIASIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
RASH
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
25.0%
1/4 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
RASH VESICULAR
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Skin and subcutaneous tissue disorders
SKIN LESION
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Vascular disorders
DEEP VEIN THROMBOSIS
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/20 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/8 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
|
Vascular disorders
HOT FLUSH
|
0.00%
0/21 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/22 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
5.0%
1/20 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/23 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
12.5%
1/8 • Number of events 1 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/18 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/13 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/4 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
0.00%
0/14 • All-cause mortality were reported from enrollment to study termination, median time on follow up was 85 days(d) for Placebo and ABBV-154 150 IV/80 SC; 87.5d for ABBV-154 300 IV/230 SC; 86d for ABBV-154 600 IV/ 530 SC; and 84d for ABBV-154 600 IV/ 530 SC E4W. Treatment-emergent and serious AE were collected from first dose until 70d after last dose; mean duration on study drug was 12 weeks for each group.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place